Immuron Limited (IMRN) AI Stock Analysis
IMRN AI stock analysis summary
AI ResearchImmuron Limited is a biotechnology company focused on polyclonal antibodies for gastrointestinal health and infectious diseases. Revenue reached $7.5M in FY2026, supported by a 5-year revenue CAGR of 120.2%, although net income remained negative at -$3.8M. The company held $9.0M in cash and short-term investments as of June 30, 2026, while its stock closed at $0.98.
- Market cap
- $7.9M
- Revenue (TTM)
- $7.7M
- P/E
- —
- 1Y return
- -55.4% S&P 500 16.8%
- Avg. target
- $3.88 295.3% vs last close
Bull case
- Immuron expanded its top line at a 5-year revenue CAGR of 120.2% from FY2021 to FY2026.
- The company maintained liquidity with $9.0M in cash and short-term investments and a current ratio of 7.17 as of June 30, 2026.
- Wall Street analysts have a mean price target of $3.88, which is 295.3% above the last close of $0.98.
Bear case
- Immuron has generated negative annual cash flow, posting free cash flow of -$3.0M in FY2026 and -$6.1M in FY2025.
- Net losses have persisted each year, ending at -$3.8M in FY2026.
- The stock delivered a 1-year return of -55.4%, lagging the S&P 500 return of 16.8%.
What Immuron does
Immuron Limited is a biopharmaceutical company based in Carlton, Australia, that researches, develops, and commercializes polyclonal antibodies. Operating through its Research and Development and Hyperimmune Products segments, the company focuses on gastrointestinal health and infectious diseases. Its flagship commercial product is Travelan, an over-the-counter medicine and dietary supplement designed to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders. It also offers Protectyn, an immune supplement aimed at maintaining healthy digestive function and liver support. Immuron is conducting a Phase III registration trial for Travelan (IMM-124E) and is developing IMM-529 in Phase I/IIa clinical trials for recurrent clostridium difficile infections.
Growth and profitability
Immuron's revenue grew from $765,193 in FY2022 to $1.8M in FY2023, $4.9M in FY2024, $7.3M in FY2025, and $7.5M in FY2026, representing a 5-year revenue CAGR of 120.2%. Top-line growth moderated to 3.5% in FY2026 after expanding 48.6% in FY2025. Gross margin was 64.5% in FY2026, compared to 65.4% in FY2025 and 96.4% in FY2023. Operating margin improved from -375.0% in FY2022 to -61.4% in FY2026. Annual net income was -$3.8M in FY2026 compared to -$5.2M in FY2025 and -$6.9M in FY2024. For the trailing twelve months ending June 30, 2026, quarterly revenue grew 7.2% year-over-year, producing total revenue of $7.7M and an operating margin of -45.1%.
Balance sheet and cash flow
As of June 30, 2026, Immuron held $9.0M in cash and short-term investments, with total assets of $13.0M and shareholders' equity of $11.0M. The company's current ratio stood at 7.17. In FY2026, operating cash flow was -$3.0M, and free cash flow was -$3.0M. Capital expenditures totaled $4,646 for the fiscal year. Over the past 5 years, Immuron's share count increased by 43.1%.
Valuation and performance
With a market capitalization of $7.9M and an enterprise value of $4.3M, Immuron trades at a price-to-sales multiple of 1.0x and an EV-to-EBITDA of 0.8x. Both are below the median of its US-listed Healthcare peers, which trade at a price-to-sales multiple of 4.1x and an EV-to-EBITDA multiple of 12.0x. Immuron's price-to-book ratio is 1.2x. Over the past year, the stock fell 55.4%, trailing the S&P 500's gain of 16.8%. Over 5 years, the stock fell 72.4% compared to an 83.0% gain for the S&P 500.
What analysts expect
Wall Street analysts report a mean price target of $3.88 for Immuron, representing 295.3% upside from the last close of $0.98 on October 16, 2026. For the current fiscal year ending June 30, 2027, the consensus revenue estimate is $9.0M, with an EPS estimate of -$0.02, reflecting an EPS growth estimate of -17.1%. The revenue estimate for the next fiscal year is $0. Over the last 4 quarters, the company recorded 0 EPS beats.
Key risks and what to watch
- Revenue growth slowed to 3.5% in FY2026 after expanding 48.6% in FY2025.
- Immuron reported an operating margin of -61.4% in FY2026, indicating ongoing operating losses.
- Shareholders face historical dilution, as the 5-year share count change was 43.1%.
- Operations are supported by a small workforce of 7 employees.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IMRN AI stock analysis
This page is an AI-written research summary of Immuron Limited (IMRN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IMRN income statement, IMRN analyst forecast, IMRN chart. See the IMRN stock overview for the latest quote and news.
IMRN AI stock analysis FAQ
What products does Immuron Limited market?
Immuron sells Travelan, an over-the-counter medicine and dietary supplement for reducing the risk of travelers' diarrhea, and Protectyn, an immune supplement for digestive and liver support.
What was Immuron's revenue in FY2026?
Immuron reported revenue of $7.5M in FY2026, representing a growth rate of 3.5% over the prior fiscal year.
Does Immuron pay a dividend?
No, Immuron does not pay a dividend.
How much cash does Immuron hold?
As of June 30, 2026, Immuron had $9.0M in cash and short-term investments with a current ratio of 7.17.
What is the analyst price target for IMRN stock?
The mean analyst price target is $3.88, which is 295.3% above its closing price of $0.98 on October 16, 2026.